Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer

Clinical Genitourinary Cancer

Volumn 9, Issue 1, 2011, Pages 31-38

  Goodman Jr , Oscar B ^a   Symanowski, James T ^a   Loudyi, Aida ^b   Fink, Louis M ^a   Ward, David C ^a   Vogelzang, Nicholas J ^a  

^a NEVADA CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NEVADA   (United States)

Author keywords

Circulating tumor cells; Hormone sensitive prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; FOLLOW UP; HORMONE SENSITIVE PROSTATE CANCER; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; PREDICTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; TESTOSTERONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; CELL COUNT; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; ORCHIECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; ROC CURVE; STATISTICS, NONPARAMETRIC; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 80053007292     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2011.04.001     Document Type: Article

References (18)

1. American Cancer Society Statistics for 2010 Facts and Figures http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-026238.pdf
2. M. Hussain, C.M. Tangen, and C. Higano Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162) J Clin Oncol 24 2006 3984 3990 (Pubitemid 46630748)
3. M. Hussain, B. Goldman, and C. Tangen Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916 J Clin Oncol 27 2009 2450 2456
4. J.S. de Bono, H.I. Scher, and R.B. Montgomery Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 2008 6302 6309
5. O.B. Goodman Jr, L.M. Fink, and J.T. Symanowski Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors Cancer Epidemiol Biomarkers Prev 18 2009 1904 1913
6. T. Okegawa, K. Nutahara, and E. Higashihara Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer J Urol 180 2008 1342 1347
7. W.J. Allard, J. Matera, and M.C. Miller Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases Clin Cancer Res 10 2004 6897 6904 (Pubitemid 39383039)
8. M. Cristofanilli, D.F. Hayes, and G.T. Budd Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer J Clin Oncol 23 2005 1420 1430
9. A. Bottomley, C. Coens, and F. Efficace Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma J Clin Oncol 25 2007 5770 5776
10. W. Sauerbrei, and M. Schumacher A bootstrap resampling procedure for model building: application to the Cox regression model Stat Med 11 1992 2093 2109 (Pubitemid 23066842)
11. D.C. Danila, G. Heller, and G.A. Gignac Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer Clin Cancer Res 13 2007 7053 7058 (Pubitemid 350276887)
12. H.I. Scher, X. Jia, and J.S. de Bono Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data Lancet Oncol 10 2009 233 239
13. R.W. Ross, W. Xie, and M.M. Regan Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect Cancer 112 2008 1247 1253 (Pubitemid 351429739)
14. C.N. Papandreou, B. Usmani, and Y. Geng Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression Nat Med 4 1998 50 57 (Pubitemid 28133079)
15. F. Chan, O. Goodman, and L. Fink Dramatically elevated circulating tumor cell numbers in a patient with small cell neuroendocrine carcinoma of the prostate Arch Pathol Lab Med 134 2010 120 123
16. S. Ishikawa, M.S. Soloway, and R. Van der Zwaag Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer J Urol 141 1989 1139 1142 (Pubitemid 19124218)
17. CALGB 90202 Clin Adv Hematol Oncol 4 2006 897 898
18. C.J. Sweeney ECOG: CHAARTED: Chemohormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer Clin Adv Hematol Oncol 4 2006 588 590